Annals of Clinical Biochemistry > Volume 45, Number 1 > Pp. 65-69

This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Ueda, K. Articles by Matsuura, N. Search for Related Content PubMed PubMed Citation Social Bookmarking                      What's this?

Original Article

Identification of L-plastin autoantibody in plasma of patients with non-Hodgkin's lymphoma using a proteomics-based analysis

Kazuhito Ueda ¹, Toyofumi Nakanishi ² , Akira Shimizu ², Takayuki Takubo ² and Nariaki Matsuura ³

¹ Central Clinical Laboratory, Osaka Medical College Hospital; ² Department of Clinical and Laboratory Medicine, Osaka Medical College, 2-7 Daigaku-cho, Takatsuki City, Osaka 569-8686; ³ Department of Molecular Pathology, Division of Health Sciences, Osaka University Graduate School of Medicine, 1-7 Yamadaoka, Suita City, Osaka 565-0871, Japan

Corresponding author: Dr Toyofumi Nakanishi. Email: nakanisi{at}poh.osaka-med.ac.jp

Background: The diagnosis of malignant lymphoma (ML) such as non-Hodgkin's lymphoma (NHL) and Hodgkin's lymphoma (HL) was mainly performed by morphological examination and gene analysis. There are only a few serum/plasma biomarkers such as lactate dehydrogenase and soluble interleukin-2 receptor to diagnose ML. The classifications are various, and therefore the cell surface markers using flow cytometry or lymph node biopsy have been examined. It is difficult, however, to distinguish the two diseases, NHL and HL, from each other.

Methods: In order to identify the haematological malignancy-associated autoimmunoreactivity (autoantibodies) in patients' plasma, a novel proteomics-based approach using electrophoresis/mass spectrometry was applied. Solubilized proteins from a Burkitt's lymphoma cell line (Raji) were separated by sodium dodecyl sulphate-polyacrylamide gel electrophoresis and Western blotting analysis, in which the plasma of individual patients with haematological malignancies was tested for primary antibodies, followed by visualization with anti-IgG antibody conjugated with horseradish peroxidase.

Results: Two proteins, L-plastin and -enolase, capable of reacting with the antibodies in plasma of patients with NHL, were detected using matrix-assisted laser desorption ionization/time-of-flight mass spectrometry and tandem mass spectrometry. The rates of the detections of an anti L-plastin autoantibody were significantly higher: 0.84 (21/25) in patients with NHL; 0.00 (0/4) in HL; 0.38 (5/13) in autoimmune diseases; 0.20 (2/10) in leukaemia; and 0.13 (1/8) in healthy controls. In contrast, those of anti -enolase antibody were not specific to NHL.

Conclusions: We first identified autoantibody against L-plastin in plasma of patients with NHL, suggesting that the autoantibody can be a new diagnostic biomarker for NHL.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?